evidence exists from comparisons with placebo in initial trials to establish the efficacy of cisapride in improving healing rates and symptoms in patients with reflux oesophagitis , in alleviating symptoms in patients with non-ulcer dyspepsia , and in accelerating gastric emptying in gastroparesis .
C0072916
cisapride
C0152020
gastroparesis